FDA Researchers Used Aborted Baby Organs To Test Monoclonal Antibody Drug Ofatumumab

Human fetal thymus, liver and bone marrow obtained from the notorious Advanced Bioscience Resources was used to humanize the BLT mice models used in a 2019 clinical study to test the monoclonal antibody drug Ofatumumab, (known as Kesimpta and used to treat multiple sclerosis).

Screenshot from the study of the list of authors, all of whom are FDA employees:

Kristina E. Howard is one of the FDA researchers listed as authors. Howard was exposed by Judicial Watch as having entered into contracts with Advanced Bioscience Resources worth $96,370 between 2012 and 2018 for "fresh and never frozen" aborted baby liver and thymic tissue for humanized mice creation.

From a Dobson Policy Center press release:

Conservative watchdog group Judicial Watch obtained hundreds of pages of emails, demonstrating that FDA official Dr. Kristina Howard contacted Advanced Bioscience Resources, explaining her attempts to make "humanized mice," and her desire "to obtain fetal liver and thymic tissues" of "at least 18 weeks gestation." Demonstrating an absolute disregard for the lives of these precious children, Howard requested "fresh" tissue and asked that it be "shipped on wet ice."

One of the tissue acquisition requests made by Kristina Howard and made available by Judicial Watch:

Kristina Howard's credentials below. She is still listed as being currently employed by the FDA on Research Gate. Please note where she received her PhD. The University of North Carolina surfaces again.

Kristina received an FDA Commissioner's fellowship in 2010 to "develop new animal models, such as immunologically humanized mice, to advance drug testing. This project will utilize immunologically humanized mice to test an approved therapeutic protein . . . "

Kristina Howard received four NIH grants for studies conducted at the University of North Carolina:

Kristina E. Howard is listed at the bottom of this graphic from the FDA describing how test mice models are humanized. The web page cited on the graphic has been removed from the FDA website.

In a 2019, Kristina Howard and other FDA researchers published a clinical study entitled, "Evaluation of the Ability of Immune Humanized Mice to Demonstrate CD20-Specific Cytotoxicity Induced by Ofatumumab" stated this as their objective:

Therefore, we tested bone marrow-liver-thymus (BLT) humanized mice to determine if they could recapitulate the pharmacokinetics (PKs), pharmacodynamics, and potential toxicities of ofatumumab, for which CDC is the predominant mechanism of action.

Screenshot from the Methods section of the paper show that researchers obtained human fetal tissues from ABR:

In the paper, the researchers explain why they specifically used BLT mice humanized with human fetal organs:

A graphic illustration of the BLT mice model can be seen below:

Screenshot from Creative Biolabs' website.

(Creative Biolabs sells BLT mice humanized with human fetal liver and thymus and promotes them for use in HIV research.)

The implications of this study are vast. First, federal taxpayer money was being used during the Trump Administration era, despite its 2019 ban on federal funding of fetal research, to purchase aborted baby organs and use them in studies conducted by FDA researchers. Conveniently, this FDA study using aborted baby organs from ABR was published in February, 2019. The Trump Admin ban on fetal tissue research occurred in February, 2019. However, the Trump Administration made an exception to the ban in 2020 when the NIH when the National Institutes of Health awarded a grant of $1.2 million to the Mouse Biology Program at the University of California, Davis, to create a cadre of humanized test mice susceptible to the COVID-19 virus, and to distribute them to researchers.

Second, it shows again the intimate connection of the University of North Carolina with the fetal industry, as has been demonstrated in many of my previous articles.

Third, it demonstrates how the use of aborted baby organs is becoming the scientific and pharmaceutical industries' standard for research and development. More on that in future articles.